Trial Profile
A 4-Week, Randomised, Double-Blind, Multicentre, Dose-Finding Phase IIb Study With AZD0865 25, 50, 75 Mg and Esomeprazole 20 Mg, Given Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis According to the LA Classification in Adult Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2009
Price :
$35
*
At a glance
- Drugs AZD 0865 (Primary) ; Esomeprazole
- Indications Gastro-oesophageal reflux; Heartburn
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 25 Aug 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 09 Sep 2008 New trial record.